127 related articles for article (PubMed ID: 38270247)
1. SN-38, an active metabolite of irinotecan, inhibits transcription of nuclear factor erythroid 2-related factor 2 and enhances drug sensitivity of colorectal cancer cells.
Wang J; Xu J; Yang S; He L; Xu W; Liu Y; Cao B; Yu S
Mol Carcinog; 2024 Apr; 63(4):742-756. PubMed ID: 38270247
[TBL] [Abstract][Full Text] [Related]
2. FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance.
Westover D; Ling X; Lam H; Welch J; Jin C; Gongora C; Del Rio M; Wani M; Li F
Mol Cancer; 2015 Apr; 14():92. PubMed ID: 25928015
[TBL] [Abstract][Full Text] [Related]
3. Modulators of the Nrf2 Signaling Pathway Enhance the Cytotoxic Effect of Standard Chemotherapeutic Drugs on Organoids of Metastatic Colorectal Cancer.
Razumovskaya AV; Silkina MO; Nikulin SV; Tonevitsky AG; Alekseev BY
Bull Exp Biol Med; 2024 Mar; 176(5):703-708. PubMed ID: 38724815
[TBL] [Abstract][Full Text] [Related]
4. Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations.
Jensen NF; Agama K; Roy A; Smith DH; Pfister TD; Rømer MU; Zhang HL; Doroshow JH; Knudsen BR; Stenvang J; Brünner N; Pommier Y
J Exp Clin Cancer Res; 2016 Mar; 35():56. PubMed ID: 27029323
[TBL] [Abstract][Full Text] [Related]
5. Cetuximab increases concentrations of irinotecan and of its active metabolite SN-38 in plasma and tumour of human colorectal carcinoma-bearing mice.
Chu C; Abbara C; Tandia M; Polrot M; Gonin P; Farinotti R; Bonhomme-Faivre L
Fundam Clin Pharmacol; 2014 Dec; 28(6):652-60. PubMed ID: 24588516
[TBL] [Abstract][Full Text] [Related]
6. Camptothecin suppresses NRF2-ARE activity and sensitises hepatocellular carcinoma cells to anticancer drugs.
Chen F; Wang H; Zhu J; Zhao R; Xue P; Zhang Q; Bud Nelson M; Qu W; Feng B; Pi J
Br J Cancer; 2017 Nov; 117(10):1495-1506. PubMed ID: 28910823
[TBL] [Abstract][Full Text] [Related]
7. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
[TBL] [Abstract][Full Text] [Related]
8. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.
Erlichman C; Boerner SA; Hallgren CG; Spieker R; Wang XY; James CD; Scheffer GL; Maliepaard M; Ross DD; Bible KC; Kaufmann SH
Cancer Res; 2001 Jan; 61(2):739-48. PubMed ID: 11212277
[TBL] [Abstract][Full Text] [Related]
9. Inhibitors of ABCB1 and ABCG2 overcame resistance to topoisomerase inhibitors in small cell lung cancer.
Omori M; Noro R; Seike M; Matsuda K; Hirao M; Fukuizumi A; Takano N; Miyanaga A; Gemma A
Thorac Cancer; 2022 Aug; 13(15):2142-2151. PubMed ID: 35719112
[TBL] [Abstract][Full Text] [Related]
10. Novel missense mutation of the DNA topoisomerase I gene in SN-38-resistant DLD-1 cells.
Arakawa Y; Suzuki H; Saito S; Yamada H
Mol Cancer Ther; 2006 Mar; 5(3):502-8. PubMed ID: 16546964
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary.
Itamochi H; Kigawa J; Sultana H; Iba T; Akeshima R; Kamazawa S; Kanamori Y; Terakawa N
Jpn J Cancer Res; 2002 Jun; 93(6):723-8. PubMed ID: 12079522
[TBL] [Abstract][Full Text] [Related]
12. Novel acrylonitrile derivatives, YHO-13177 and YHO-13351, reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo.
Yamazaki R; Nishiyama Y; Furuta T; Hatano H; Igarashi Y; Asakawa N; Kodaira H; Takahashi H; Aiyama R; Matsuzaki T; Yagi N; Sugimoto Y
Mol Cancer Ther; 2011 Jul; 10(7):1252-63. PubMed ID: 21566063
[TBL] [Abstract][Full Text] [Related]
13. Long-lasting reduction in clonogenic potential of colorectal cancer cells by sequential treatments with 5-azanucleosides and topoisomerase inhibitors.
Pawlak A; Ziolo E; Fiedorowicz A; Fidyt K; Strzadala L; Kalas W
BMC Cancer; 2016 Nov; 16(1):893. PubMed ID: 27852227
[TBL] [Abstract][Full Text] [Related]
14. DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant.
Joto N; Ishii M; Minami M; Kuga H; Mitsui I; Tohgo A
Int J Cancer; 1997 Aug; 72(4):680-6. PubMed ID: 9259410
[TBL] [Abstract][Full Text] [Related]
15. Differential activity of topotecan, irinotecan and SN-38 in fresh human tumour cells but not in cell lines.
Jonsson E; Dhar S; Jonsson B; Nygren P; Graf W; Larsson R
Eur J Cancer; 2000 Oct; 36(16):2120-7. PubMed ID: 11044651
[TBL] [Abstract][Full Text] [Related]
16. Pregnane X Receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation.
Raynal C; Pascussi JM; Leguelinel G; Breuker C; Kantar J; Lallemant B; Poujol S; Bonnans C; Joubert D; Hollande F; Lumbroso S; Brouillet JP; Evrard A
Mol Cancer; 2010 Mar; 9():46. PubMed ID: 20196838
[TBL] [Abstract][Full Text] [Related]
17. Bone marrow and tumor cell colony-forming units and human tumor xenograft efficacy of noncamptothecin and camptothecin topoisomerase I inhibitors.
Kurtzberg LS; Battle T; Rouleau C; Bagley RG; Agata N; Yao M; Schmid S; Roth S; Crawford J; Krumbholz R; Ewesuedo R; Yu XJ; Wang F; Lavoie EJ; Teicher BA
Mol Cancer Ther; 2008 Oct; 7(10):3212-22. PubMed ID: 18852125
[TBL] [Abstract][Full Text] [Related]
18. Acquired irinotecan resistance is accompanied by stable modifications of cell cycle dynamics independent of MSI status.
Petitprez A; Poindessous V; Ouaret D; Regairaz M; Bastian G; Guérin E; Escargueil AE; Larsen AK
Int J Oncol; 2013 May; 42(5):1644-53. PubMed ID: 23546019
[TBL] [Abstract][Full Text] [Related]
19. Schlafen-11 sensitizes colorectal carcinoma cells to irinotecan.
Tian L; Song S; Liu X; Wang Y; Xu X; Hu Y; Xu J
Anticancer Drugs; 2014 Nov; 25(10):1175-81. PubMed ID: 25089570
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.
Takiguchi S; Kumazawa E; Shimazoe T; Tohgo A; Kono A
Jpn J Cancer Res; 1997 Aug; 88(8):760-9. PubMed ID: 9330608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
